To arrange a media interview with Ellie Smeal or other spokespersons at Feminist Majority Foundation, contact the FMF media department at 703-522-2214.
Feminist Majority Foundation Applauds Giant Step Forward on Mifepristone FDA Approval
Today's announcement that the Food and Drug Administration has found mifepristone (formerly known as RU 486) "approvable" for early medical abortion represents a hard-won victory for the U.S. feminist movement, for the scientific and medical community, and, most importantly, for the women of this nation.
The FDA has put science ahead of politics. This milestone marks a giant step forward both in making mifepristone available to American women and in assuring the conduct of desperately needed research on the non-abortion indications of this life-saving medication.
The FDA has confirmed what women in Great Britain, France, and Sweden already know: Mifepristone is safe. It is effective. And, it's availability greatly benefits women.
For eight long years, the Feminist Majority Foundation has fought to bring mifepristone to the United States. We have worked to remove roadblock after roadblock to introduce this medical breakthrough into this country.
Again and again, the strength and breadth of support for mifepristone has dwarfed anti-abortion opposition. The Feminist Majority Foundation has delivered over 700,000 petitions to Roussel Uclaf and Hoechst AG urging release of the compound. We have organized meetings between the European pharmaceutical firms and delegations of feminist leaders and prominent scientists. We have won support for mifepristone from every major women's rights organization and medical and scientific association. Over 66% of women and men believe mifepristone should be available to women in the United States -- an unprecedentedlevel of support for a medication which is still not available.
The FDA's "approvable" rating -- which is the typical next step in the approval process -- moves us closer and closer to the introduction of mifepristone in the United States. With the continued vigilance of pro-choice organizations, we hope that final FDA approval will come quickly.